COMMUNIQUÉS West-GlobeNewswire

-
EHNAC Announces Finalized 2018 Accreditation Criteria Versions for All Accreditation Programs
15/01/2018 -
LIDDS: Nyenburgh Holding invests 13,5 MSEK in a direct share issue
15/01/2018 -
Zealand Pharma major shareholder announcement: Royce & Associates, LLC, U.S.
15/01/2018 -
Ochsner Health System and Vital Images® Announce New Partnership
15/01/2018 -
MPI's spinout Oncology Venture will execute license to multi TKI phase 3 compound
15/01/2018 -
Scythian Biosciences Announces CEOs of Both Aphria and Liberty Health Sciences are Joining its Board
15/01/2018 -
Canada’s Leading Cannabis Health Care Service Signs First-of-its-kind Agreement with Durham College
15/01/2018 -
Extendicare Announces January 2018 Dividend of C$0.04 per Share
15/01/2018 -
REPEAT: Cannabis Wheaton Income Corp. Launches Kolab Project
15/01/2018 -
Renaissance BioScience Corp. Retains Blair Jordan as Capital Markets Advisor
15/01/2018 -
MPX Signs Agreement With Israeli Pharmaceutical Company Panaxia for the Production and Marketing of Pharma-Grade Cannabinoid Products
15/01/2018 -
Avivagen Announces Positive Results from Swine Trial
15/01/2018 -
Cytovance® Biologics Welcomes Edwin Miranda as Vice President of Quality
15/01/2018 -
Xbrane Biopharma clarifies information regarding letter of intent with CR Pharma considering Xlucane
15/01/2018 -
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
15/01/2018 -
Immunicum AB (publ) Initiates Trading of Shares on Nasdaq Stockholm
15/01/2018 -
Shire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A
15/01/2018 -
TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601
15/01/2018 -
TiGenix annonce la publication dans Gastroenterology des résultats de la semaine 52 de l'essai de phase III ADMIRE-CD du Cx601
15/01/2018
Pages